Exploration reveals SSR2 drives hepatocellular carcinoma progression through altered immune pathways.
In hepatocellular carcinoma (HCC), the high expression of the SSR2 gene in NK cells is accompanied by enhanced cytoplasmic translation pathway, which promotes MIF secretion and activates its downstream signaling pathways, thereby driving the disruption of the tumor immune microenvironment and the progression of the disease.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: